A Master Protocol for Biomarker-Based Treatment of AML (The Beat AML Trial)
Phase of Trial: Phase I/II
Latest Information Update: 04 Apr 2017
At a glance
- Drugs Samalizumab (Primary) ; Enasidenib; Entospletinib
- Indications Acute myeloid leukaemia
- Focus Therapeutic Use
- Acronyms BEAT AML Master Trial
- 16 Feb 2017 According to Alexion Pharmaceuticals media release, patients are being dosed in this trial.
- 13 Dec 2016 According to Alexion Pharmaceuticals' website, the Leukemia and Lymphoma Society is conducting this trial.
- 13 Dec 2016 Status changed from planning to recruiting, based on the information present in Alexion Pharmaceuticals website.